Inclusion Criteria:

          -  Age 18 or older

          -  Diagnosis of histologically confirmed glioblastoma (WHO grade IV). Subjects with an
             original histologic diagnosis of low grade glioma or anaplastic glioma (WHO grade II
             or III) are eligible if a subsequent histological diagnosis of glioblastoma is made

          -  Patients whose tumor is determined to be unmethylated

          -  Patients with incomplete resection as determined by residual, measurable gadolinium or
             contrast-enhancing lesion or lesions

          -  Recent resection of glioblastoma within 4 weeks of study entry. Patients who have only
             had a tumor biopsy and who are considered unresectable are eligible (but based on the
             study accrual this subset of patients with unresectable tumor may be considered for
             separate analysis)

          -  ECOG PS of ≤ 2 (see appendix A)

          -  Willing to remain abstinent from consuming alcohol while on DSF

          -  No prior radiation or chemotherapy

          -  Meets the following laboratory criteria:

               -  Absolute neutrophil count ≥ 1,500/mcL

               -  Platelets ≥ 100,000/mcL

               -  Hemoglobin > 10.0 g/dL (transfusion and/or ESA allowed)

               -  Total bilirubin and alkaline phosphatase ≤ 2x institutional upper limit of normal
                  (ULN)

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN

               -  Blood urea nitrogen (BUN) and creatinine < 1.5 x ULN

          -  Able to take oral medication

          -  Able to understand and willing to sign an institutional review board (IRB)-approved
             written informed consent document (legally authorized representative permitted)

        Exclusion Criteria:

          -  Radiographic evidence of leptomeningeal dissemination, extensive intraparenchymal
             dissemination, infratentorial tumor, or metastatic disease to sites remote from the
             supratentorial brain

          -  Enrolled in another clinical trial testing a novel therapy or drug

          -  Received prior radiation therapy or chemotherapy for glioblastoma

          -  History of allergic reaction/hypersensitivity to DSF (without alcohol) or copper.

          -  Treatment with the following medications that may interfere with metabolism of DSF:
             warfarin (unless otherwise chosen by the study PI who will actively adjust Coumadin
             dose to consistently maintain a safe, therapeutic INR < 3), theophylline,
             amitriptyline, isoniazid, metronidazole, phenytoin, phenobarbital, chlorzoxazone,
             halothane, imipramine, chlordiazepoxide, diazepam. (Note: lorazepam and oxazepam are
             not affected by the P450 system and are not contraindicated with DSF).

          -  Active severe hepatic or renal disease

          -  Grade 2 or higher peripheral neuropathy or ataxia per NCI CTCAE version 4.0 (2009)

          -  History of idiopathic seizure disorder schizophrenia, or psychosis unrelated to
             glioblastoma, corticosteroid, or anti-epileptic medications

          -  History of Wilson's or Gilbert's disease

          -  Current excessive use of alcohol